Emerging Role of Vedolizumab in Managing Refractory Immune Checkpoint Inhibitor–Induced Enteritis

We report a 62-year-old white woman with metastatic choroidal melanoma who developed immune checkpoint inhibitor (ICI)-induced enteritis and grade 3 diarrhea refractory to steroids and infliximab. Her diarrhea quickly resolved after infusion of vedolizumab, and the patient was able to taper down ste...

Descripción completa

Detalles Bibliográficos
Autores principales: Diana, Pietro, Mankongpaisarnrung, Charoen, Atkins, Michael B., Zeck, Jay C., Charabaty, Aline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American College of Gastroenterology 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830540/
https://www.ncbi.nlm.nih.gov/pubmed/29516018
http://dx.doi.org/10.14309/crj.2018.17
_version_ 1783303016975171584
author Diana, Pietro
Mankongpaisarnrung, Charoen
Atkins, Michael B.
Zeck, Jay C.
Charabaty, Aline
author_facet Diana, Pietro
Mankongpaisarnrung, Charoen
Atkins, Michael B.
Zeck, Jay C.
Charabaty, Aline
author_sort Diana, Pietro
collection PubMed
description We report a 62-year-old white woman with metastatic choroidal melanoma who developed immune checkpoint inhibitor (ICI)-induced enteritis and grade 3 diarrhea refractory to steroids and infliximab. Her diarrhea quickly resolved after infusion of vedolizumab, and the patient was able to taper down steroids. Vedolizumab’s mechanism of action and its gut specificity have the potential to reverse immune-induced enterocolitis without neutralizing or reversing the therapeutic benefit of ICI on the malignancy.
format Online
Article
Text
id pubmed-5830540
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher American College of Gastroenterology
record_format MEDLINE/PubMed
spelling pubmed-58305402018-03-07 Emerging Role of Vedolizumab in Managing Refractory Immune Checkpoint Inhibitor–Induced Enteritis Diana, Pietro Mankongpaisarnrung, Charoen Atkins, Michael B. Zeck, Jay C. Charabaty, Aline ACG Case Rep J Case Report We report a 62-year-old white woman with metastatic choroidal melanoma who developed immune checkpoint inhibitor (ICI)-induced enteritis and grade 3 diarrhea refractory to steroids and infliximab. Her diarrhea quickly resolved after infusion of vedolizumab, and the patient was able to taper down steroids. Vedolizumab’s mechanism of action and its gut specificity have the potential to reverse immune-induced enterocolitis without neutralizing or reversing the therapeutic benefit of ICI on the malignancy. American College of Gastroenterology 2018-02-28 /pmc/articles/PMC5830540/ /pubmed/29516018 http://dx.doi.org/10.14309/crj.2018.17 Text en Copyright © Diana et al. This is an open-access article. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Case Report
Diana, Pietro
Mankongpaisarnrung, Charoen
Atkins, Michael B.
Zeck, Jay C.
Charabaty, Aline
Emerging Role of Vedolizumab in Managing Refractory Immune Checkpoint Inhibitor–Induced Enteritis
title Emerging Role of Vedolizumab in Managing Refractory Immune Checkpoint Inhibitor–Induced Enteritis
title_full Emerging Role of Vedolizumab in Managing Refractory Immune Checkpoint Inhibitor–Induced Enteritis
title_fullStr Emerging Role of Vedolizumab in Managing Refractory Immune Checkpoint Inhibitor–Induced Enteritis
title_full_unstemmed Emerging Role of Vedolizumab in Managing Refractory Immune Checkpoint Inhibitor–Induced Enteritis
title_short Emerging Role of Vedolizumab in Managing Refractory Immune Checkpoint Inhibitor–Induced Enteritis
title_sort emerging role of vedolizumab in managing refractory immune checkpoint inhibitor–induced enteritis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830540/
https://www.ncbi.nlm.nih.gov/pubmed/29516018
http://dx.doi.org/10.14309/crj.2018.17
work_keys_str_mv AT dianapietro emergingroleofvedolizumabinmanagingrefractoryimmunecheckpointinhibitorinducedenteritis
AT mankongpaisarnrungcharoen emergingroleofvedolizumabinmanagingrefractoryimmunecheckpointinhibitorinducedenteritis
AT atkinsmichaelb emergingroleofvedolizumabinmanagingrefractoryimmunecheckpointinhibitorinducedenteritis
AT zeckjayc emergingroleofvedolizumabinmanagingrefractoryimmunecheckpointinhibitorinducedenteritis
AT charabatyaline emergingroleofvedolizumabinmanagingrefractoryimmunecheckpointinhibitorinducedenteritis

Ejemplares similares